Literature DB >> 34422107

A case series of non-valvular cardiac aspergillosis in critically ill solid organ transplant and non-transplant patients and systematic review.

Annalan Md Navaratnam1, Mohammad Al-Freah1, Anna Cavazza1, Georg Auzinger1,2.   

Abstract

INTRODUCTION: Non-valvular cardiac aspergillosis is a rare infection of the pericardium, myocardium or endocardium and is associated with a high mortality. There is a paucity of reports of non-valvular cardiac aspergillosis in critically ill and solid organ transplant (SOT) patients. The majority of cases have been reported in haemato-oncology patients, some of whom have undergone a bone marrow transplant.
OBJECTIVES: We describe four cases affected by non-valvular cardiac aspergillosis in the intensive care setting including a systematic review of this extremely rare infection which is associated with high mortality.
RESULTS: All four-patients died but presented with varying clinical, radiological and microbiological evidence of the disease. Three patients presented following complications after solid organ transplantation, two in the context of acute liver failure and emergency liver transplant and one several years after a double lung transplant. The last patient presented with necrotising gall stone pancreatitis, multi-organ failure and subsequently a prolonged intensive care unit (ICU) stay. On review of the literature, January 1955 to July 2019, 45 cases were identified, with different risk factors, clinical and radiological manifestations, treatment regimen and outcome.
CONCLUSION: Antemortem diagnosis of cardiac aspergillosis is difficult and rare, with no cases reporting positive blood culture results. Galactomannan serology has poor sensitivity in solid organ transplant patients, further reduced by prophylactic antimicrobial treatment, which is common in the ICU setting especially post-transplant patients. Due to the scarcity of cases, treatment is extrapolated from invasive aspergillosis management, with emphasis on early treatment with combination therapy. © The Intensive Care Society 2020.

Entities:  

Keywords:  Solid organ transplantation; anti-fungal; fungaemia; intensive care; voriconazole

Year:  2020        PMID: 34422107      PMCID: PMC8373280          DOI: 10.1177/1751143720936821

Source DB:  PubMed          Journal:  J Intensive Care Soc        ISSN: 1751-1437


  29 in total

1.  Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies.

Authors:  Olivier Adam; Anne Aupérin; Fanny Wilquin; Jean-Henri Bourhis; Bertrand Gachot; Elisabeth Chachaty
Journal:  Clin Infect Dis       Date:  2004-02-27       Impact factor: 9.079

Review 2.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

3.  Survival after disseminated invasive aspergillosis in a multivisceral transplant recipient.

Authors:  R Vianna; V Misra; J A Fridell; M Goldman; R S Mangus; J Tector
Journal:  Transplant Proc       Date:  2007 Jan-Feb       Impact factor: 1.066

4.  Long-Term Favorable Course of Aspergillus Endo-, Myo-, and Pericarditis.

Authors:  Akiko Hayashi; Sayuki Kobayashi; Itaru Hisauchi; Takaaki Komatsu; Shiro Nakahara; Yoshihiko Sakai; Kosuke Haruki; Isao Taguchi
Journal:  Int Heart J       Date:  2017-11-22       Impact factor: 1.862

Review 5.  Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen.

Authors:  F Ader; S Nseir; R Le Berre; S Leroy; I Tillie-Leblond; C H Marquette; A Durocher
Journal:  Clin Microbiol Infect       Date:  2005-06       Impact factor: 8.067

6.  Rapidly advancing invasive endomyocardial aspergillosis.

Authors:  Vedat Davutoglu; Serdar Soydinc; Abdullah Aydin; Metin Karakok
Journal:  J Am Soc Echocardiogr       Date:  2005-02       Impact factor: 5.251

7.  Medical management of Aspergillus flavus endocarditis.

Authors:  K Rao; V Saha
Journal:  Pediatr Hematol Oncol       Date:  2000 Jul-Aug       Impact factor: 1.969

8.  Invasive aspergillosis in critically ill patients: analysis of risk factors for acquisition and mortality.

Authors:  K Vandewoude; S Blot; D Benoit; P Depuydt; D Vogelaers; F Colardyn
Journal:  Acta Clin Belg       Date:  2004 Sep-Oct       Impact factor: 1.264

9.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Authors:  Raoul Herbrecht; David W Denning; Thomas F Patterson; John E Bennett; Reginald E Greene; Jörg-W Oestmann; Winfried V Kern; Kieren A Marr; Patricia Ribaud; Olivier Lortholary; Richard Sylvester; Robert H Rubin; John R Wingard; Paul Stark; Christine Durand; Denis Caillot; Eckhard Thiel; Pranatharthi H Chandrasekar; Michael R Hodges; Haran T Schlamm; Peter F Troke; Ben de Pauw
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

10.  Successful management of invasive aspergillosis presenting as pericarditis in an adult patient with chronic granulomatous disease.

Authors:  Klaus L Mortensen; Jane B Knudsen; Søren Jensen-Fangel; Brian Stausbøl-Grøn; Maiken C Arendrup; Eskild Petersen
Journal:  Mycoses       Date:  2009-12-23       Impact factor: 4.377

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.